Mismatch repair deficiency predicts response of solid tumors to PD-1 blockadeDung T. Le, Luis A. Díaz, Cara Wilt et al.|Science|2017Cited by 6.6k
Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic CancerTakahiro Tsujikawa, Dung T. Le, Todd S. Crocenzi et al.|Clinical Cancer Research|2020Cited by 151
Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) BlockadeJuan C. Osorio, Matthew D. Hellmann, Kathryn C. Arbour et al.|Journal of Clinical Oncology|2019Cited by 134
A phase 1 trial of the oral DNA methyltransferase inhibitor CC‐486 and the histone deacetylase inhibitor romidepsin in advanced solid tumorsStéphanie Gaillard, Nilofer S. Azad, Marianna Zahurak et al.|Cancer|2019Cited by 56